Carotid Artery ImPlant for Trapping UpstReam Emboli (CAPTURE 2) for Preventing Stroke in Atrial Fibrillation Patients Taking Oral Anticoagulants
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 100
- 试验地点
- 17
- 主要终点
- Number of participants that had Ischemic Stroke and/or Hemorrhagic stroke and/or implantation procedure complications
研究概览
简要总结
This study will assess the safety and performance of the Vine™ Embolic Protection System (embolic filtering device) in atrial fibrillation (AF) patients on top of oral anticoagulants (OAC), and remain at high risk for stroke recurrence. All patients will receive bilateral implants in the common carotid arteries
详细描述
The Vine™ filter (Vine™ or implant) is a permanent carotid filter designed for stroke prevention in AF patients taking OAC at high stroke risk (CHA2DS2-VASc ≤ 4 and stroke history). This patient population accounts for ~20% of the entire AF population, which is ~300K/year in the United State and EU. The implant is designed to exclude emboli > 1.4mm in size from reaching the anterior circulation. In AF patients, approximately 80% of strokes are total or partial anterior circulation strokes caused by occlusions of the main branches of the Circle of Willis, mainly M1-2, and rarely A1-2. The diameter of these branches, in the majority of cases, is > 1.5 mm
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 50 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Documented AF
- •CHA2DS2-VASc score ≥ 4 and history of ischemic stroke (including TIA with positive neuro-imaging)
- •No contra-indication for patient to receive an OAC, either vitamin K antagonist (VKA) or novel oral anticoagulant (NOAC) for the duration of the study
- •Age > 50 years
- •Maximal (systolic) CCA diameter range: ≥ 4.8mm and ≤ 9.8mm
- •CCA accessibility: up to 40mm from skin to CCA center, safe approach
- •Implantation segment free of atherosclerotic disease as determined by ultrasound imaging
- •Patient is able and willing to provide informed consent
排除标准
- •Evidence of carotid stenosis > 30% [CCA, internal carotid artery (ICA), or external carotid artery (ECA)]
- •Evidence of carotid dissection
- •Pre-existing stent(s) in CCA
- •Female who is pregnant or who is planning to become pregnant during the course of the study
- •Life expectancy of less than two years
- •Active systemic infection
- •Known sensitivity to nickel or titanium metals, or their alloys
- •Known hereditary or acquired coagulation disorders
- •Any planned surgical or endovascular treatment within 30 days after the implantation procedure
- •A co-morbid disease or condition that could confound the neurological and functional evaluations or compromise survival or ability to complete follow-up assessments* Current use or a recent history of illicit drug(s) use or alcohol abuse (defined as regular or daily consumption of more than four alcoholic drinks per day)
- •Active participation in another investigational drug or device treatment study
- •Inability to complete all scheduled follow-up
- •Any other condition that in the opinion of the investigator may adversely affect the safety of the patient or would limit the patient's ability to complete the study
- •History of intracerebral hemorrhage (ICH) and/or hemorrhagic stroke
- •Event of stroke/TIA in the past 14 days
研究组 & 干预措施
Vine™ Filter + OAC
Vine™ Filter in each common carotid artery (CCA) with oral anticoagulant treatment (either vitamin K antagonist (VKA) or novel oral anticoagulant (NOAC)) for the duration of the study
干预措施: Vine™ Embolic Protection System (Device)
结局指标
主要结局
Number of participants that had Ischemic Stroke and/or Hemorrhagic stroke and/or implantation procedure complications
时间窗: 30 days from implantation procedure
Major Adverse Events (MAEs) within 30 days of the final index (implantation) procedure, defined as the composite that includes any of the following: * Any ischemic stroke with ischemic foci confined to the territories of Vine™ implanted arteries * Hemorrhagic stroke or major hemorrhage while receiving additional antithrombotic therapy required for Vine™ implantation * Any Vine™ or Vine™ implantation procedure-related complication that requires surgery or endovascular treatment, or results in death or major disability
次要结局
- Number of participants that had disabling strokes(30 days, one and two years from implantation procedure)
- Number of observed thrombi on the device(30 days, one and two years from implantation procedure)
- Number of participants that had Ischemic Stroke and/or Hemorrhagic stroke and/or Device complications.(one and two years from implantation procedure)
- Number of properly positioned implants(one and two years from implantation procedure)
- Number of death cases(one and two years from implantation procedure)
- Number of strokes (any kind)(one and two years from implantation procedure)
- Number of Implantation success(immediately after the procedure)
- Number of properly positioned implants(30 days from implantation procedure)